"Deoxycytidine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE.
| Descriptor ID |
D003841
|
| MeSH Number(s) |
D03.383.742.680.245.500 D13.570.230.329 D13.570.685.245.500
|
| Concept/Terms |
Deoxycytidine- Deoxycytidine
- Cytosine Deoxyribonucleoside
- Deoxyribonucleoside, Cytosine
- Cytosine Deoxyriboside
- Deoxyriboside, Cytosine
|
Below are MeSH descriptors whose meaning is more general than "Deoxycytidine".
Below are MeSH descriptors whose meaning is more specific than "Deoxycytidine".
This graph shows the total number of publications written about "Deoxycytidine" by people in this website by year, and whether "Deoxycytidine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 2 | 3 |
| 2000 | 4 | 0 | 4 |
| 2001 | 4 | 2 | 6 |
| 2002 | 9 | 0 | 9 |
| 2003 | 2 | 0 | 2 |
| 2004 | 7 | 0 | 7 |
| 2005 | 5 | 5 | 10 |
| 2006 | 3 | 3 | 6 |
| 2007 | 0 | 6 | 6 |
| 2008 | 4 | 5 | 9 |
| 2009 | 3 | 2 | 5 |
| 2010 | 2 | 1 | 3 |
| 2011 | 4 | 12 | 16 |
| 2012 | 3 | 6 | 9 |
| 2013 | 3 | 3 | 6 |
| 2014 | 1 | 4 | 5 |
| 2015 | 0 | 4 | 4 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 1 | 2 |
| 2018 | 3 | 5 | 8 |
| 2019 | 1 | 3 | 4 |
| 2020 | 1 | 1 | 2 |
| 2021 | 2 | 1 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 3 | 3 |
| 2025 | 0 | 2 | 2 |
| 2026 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Deoxycytidine" by people in Profiles.
-
Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing Schedules. Clin Genitourin Cancer. 2026 Aug; 24(5):102577.
-
Alopecia following single-dose postoperative intravesical gemcitabine in nonmuscle-invasive bladder cancer: A multi-institutional case series. Urol Oncol. 2026 Mar; 44(3):110984.
-
Carboplatin, gemcitabine, and mifepristone for advanced breast and recurrent/persistent epithelial ovarian cancer. Breast Cancer Res Treat. 2025 Oct; 213(3):347-354.
-
Conversion to Resection After Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Borderline Resectable CCA: A Real-World Exploratory Analysis. Ann Surg Oncol. 2025 Oct; 32(10):7215-7227.
-
A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell Lymphomas. Clin Lymphoma Myeloma Leuk. 2025 May; 25(5):328-336.
-
Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial. Eur J Cancer. 2024 Sep; 209:114236.
-
Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer. JCO Precis Oncol. 2024 04; 8:e2300274.
-
Co-delivery of three synergistic chemotherapeutics in a core-shell nanoscale coordination polymer for the treatment of pancreatic cancer. Biomaterials. 2023 10; 301:122235.
-
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. Clin Cancer Res. 2022 09 15; 28(18):3990-4002.
-
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2021 10; 22(10):1438-1447.